PRAXIS PRECISION MEDICINES, INC. PRAX 深 滬
已收盤 11-14 16:00:00 美东时间
186.42
+8.340
+4.68%
華盛通- 最 高197.55
- 今 開178.08
- 成交量 86.81万股
- 最 低 175.79
- 昨 收 178.08
- 總市值 39.24亿
- 52周最高 206.71
- 市盈率 靜 --
- 換手率 4.12%
- 52周最低 26.70
- 委 比 -27.27%
- 總股本 2104.96万
- 歷史最高 914.265
- 量 比 1.66
- 振 幅 12.22%
- 歷史最低 11.85
- 每 手 1
- 風險率 38.92%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 思科、On Holding、派拓网络等获多家机构上调目标价；Circle 遭富国、德银等多家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持PDS Biotechnology"买入"评级，目标价从13美元升至15美元；HC Wainwright & Co.：维持PepGen Inc."买入"评级，目标价从18美元升至20美元
11-14 10:43
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX) and GoodRx Holdings (GDRX)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
11-10 09:20
美股大行评级 | 绩后评级扎堆！高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；DoorDash、多邻国、Figma、飞塔信息、HubSpot等遭下调目标价
高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；Adient、DoorDash、多邻国、Figma、飞塔信息、HubSpot、康丽数码等遭大行下调目标价
11-07 10:14
Wedbush Maintains Underperform on Praxis Precision Medicine, Raises Price Target to $77
Wedbush analyst Laura Chico maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Underperform and raises the price target from $73 to $77.
11-06 21:30
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines granted 6,876 restricted stock units to six new non-executive employees under the 2024 Inducement Plan. The awards were made to incentivize employment, with units vesting over four years.
11-06 13:00
Praxis Precision Medicine Q3 EPS $(3.36) Beats $(3.43) Estimate
Praxis Precision Medicine (NASDAQ:PRAX) reported quarterly losses of $(3.36) per share which beat the analyst consensus estimate of $(3.43) by 1.96 percent. This is a 22.18 percent decrease over losses of $(2.75) per
11-05 21:04
Praxis announces accelerated development path for relutrigine in SCN2A and SCN8A DEE patients following positive FDA feedback
Praxis Precision Medicines held a comprehensive meeting with the FDA in Q3, aligning on key aspects of the relutrigine program for SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs). The company plans to conduct an interim analysis of the EMBOLD cohort 2 pivotal trial in Q4 2025, which, if positive, will serve as the basis for an NDA submission in early 2026. Relutrigine is the first-in-class therapy targeting neuronal excitation...
11-04 13:00
Kimberly-Clark, Vertex And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Nasdaq futures gaining mor...
11-03 21:14
Praxis Precision Medicines Advances Elsunersen Trial for Pediatric Epileptic Encephalopathy
Praxis Precision Medicines, Inc. (($PRAX)) announced an update on their ongoing...
10-28 05:57
Praxis Precision Medicines Updates Corporate Presentation
Praxis Precision Medicines ( ($PRAX) ) just unveiled an announcement. On Octobe...
10-21 20:28
